A Randomized Phase II Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) in Patients With Low-Grade Cervical Intraepithelial Neoplasia (CIN1)

Trial Profile

A Randomized Phase II Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) in Patients With Low-Grade Cervical Intraepithelial Neoplasia (CIN1)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2015

At a glance

  • Drugs Hexyl aminolevulinate (Primary)
  • Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Therapeutic Use
  • Sponsors PhotoCure
  • Most Recent Events

    • 26 Jun 2012 Actual patient number changed from 70 to 83 as reported by ClinicalTrials.gov.
    • 26 Jun 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 26 Jun 2012 Planned end date changed from 1 Dec 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top